Table I.

Characteristics and basal hormone levels of normal (control) rhesus monkeys (Macaca mulatta) and monkeys that underwent PA and recombinant human FSH (rhFSH) therapy for IVF^a

Females	Normal (n = 6)	Early-treated PA (n = 5)	Late-treated PA (n = 3)
Age (years)*	21.6 ± 0.7	23.3 ± 0.8	19.2 ± 1.1b
BMI (kg/m2)*	43.0 ± 2.1	34.7 ± 2.3	38.4 ± 2.9
Serum FSH (ng/ml)**	3.2 (2.3, 4.3)	2.4 (1.6, 3.5)	2.4 (1.5, 3.6)
Serum bioactive LH (ng/ml)**	0.3 (0.2, 0.6)	0.3 (0.2, 0.5)	0.3 (0.1, 0.6)
Serum E2 (nmol/l)**	0.72 (0.39, 1.35)	0.14 (0.07, 0.27)c	0.10 (0.04, 0.26)c
Serum progesterone (nmol/l)**	0.64 (0.32, 0.95)	0.32 (0.32, 0.64)	0.32 (0.32, 0.64)
Serum 17OHP4 (nmol/l)**	0.30 (0.30, 0.91)	0.61 (0.30, 1.21)	0.61 (0.30, 2.42)
Serum A4 (nmol/l)*	0.69 ± 0.11	0.99 ± 0.12	1.16 ± 0.15
Serum testosterone (nmol/l)*	0.68 ± 0.14	0.91 ± 0.15	0.85 ± 0.19
Serum DHT (nmol/l)*	0.51 ± 0.10	0.45 ± 0.11	0.56 ± 0.14

17OHP₄: 17-hydroxyprogesterone, DHT: dihydrotestosterone, A₄: androstenedione, E₂: estradiol, early-treated PA: starting PA on days 40–44 postconception (total gestation, 165 days), late treated PA: starting PA on days 100–115 postconception.

^aMean ± SE*, back-transformed log₁₀ mean (95% CI)**.

^bP < 0.025 versus early-treated PA females.

^cP < 0.01 versus normal females.